Evidence map›Paper›PMID 38922500›Full record

ArticleCell biology and toxicology2024

SPACA6P-AS: a trailblazer in breast cancer pathobiology and therapeutics.

Wenjie Feng, Yiling Jiang, Lijun Zeng, Yuhan Ouyang, Hailong Li, Yuanbin Tang, Lunqi Luo, Lianjie Ouyang, Liming Xie, Yeru Tan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenjie FengDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Yiling JiangDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Lijun ZengDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Yuhan OuyangDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Hailong LiDepartment of Pathology, Changde Hospital, Xiangya School of Medicine, Central South University, the First People's Hospital of Changde City, Changde, Hunan, People's Republic of China.
Yuanbin TangDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Lunqi LuoDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Lianjie OuyangDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Liming XieDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China. xlmusc@163.com.
Yeru TanDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China. tanyeru@163.com.
Yuehua LiDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China. liyuehua2020@stu.usc.edu.cn.

Funding

Clinical Medical Research 4310 Program of the University of South China 20224310NHYCG07Key Research Project of Hunan Provincial Education Department 21A0270Natural Science Foundation of Hunan Province 2023JJ60496 and S2024JJBMLH0555Scientific Research Fund Project of Hunan Provincial Health Commission B202303109577 and D202303109191
6 · The paper itself

Abstract

objectiveThe primary objective of this investigation is to delve into the involvement of the long noncoding RNA (lncRNA) SPACA6P-AS in breast cancer (BC) development, focusing on its expression pattern, association with clinical-pathological features, impact on prognosis, as well as its molecular and immunological implications.

methodsBioinformatics analysis was conducted utilizing RNA sequencing data of 1083 BC patients from the TCGA database. Functional exploration of SPACA6P-AS was carried out through the construction of survival curves, GO and KEGG enrichment analysis, and single-sample gene set enrichment analysis (ssGSEA). Furthermore, its functionality was validated through in vitro cell experiments and in vivo nude mouse model experiments.

resultsSPACA6P-AS showed a remarkable increase in expression levels in BC tissues (p < 0.001) and demonstrated a close relationship to poor prognosis (overall survival HR = 1.616, progression-free interval HR = 1.40, disease-specific survival HR = 1.54). Enrichment analysis revealed that SPACA6P-AS could impact biological functions such as protease regulation, endopeptidase inhibitor activity, taste receptor activity, taste transduction, and maturity-onset diabetes of the young pathway. ssGSEA analysis indicated a negative correlation between SPACA6P-AS expression and immune cell infiltration like dendritic cells and neutrophils, while a positive correlation was observed with central memory T cells and T helper 2 cells. Results from in vitro and in vivo experiments illustrated that silencing SPACA6P-AS significantly inhibited the proliferation, migration, and invasion capabilities of BC cells. In vitro experiments also highlighted that dendritic cells with silenced SPACA6P-AS exhibited enhanced capabilities in promoting the proliferation of autologous CD3 + T cells and cytokine secretion. These discoveries elucidate the potential multifaceted roles of SPACA6P-AS in BC, including its potential involvement in modulating immune cell infiltration in the tumor microenvironment.

conclusionThe high expression of lncRNA SPACA6P-AS in BC is closely linked to poor prognosis and may facilitate tumor progression by influencing specific biological processes, signaling pathways, and the immune microenvironment. The regulatory role of SPACA6P-AS positions it as a prospective biomarker and target for therapeutic approaches for BC diagnosis and intervention.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticMice, NudeRNA, Long NoncodingAnimalsCell Line, TumorCell MovementCell ProliferationComputational BiologyFemaleHumansMiceMice, Inbred BALB CMiddle AgedPrognosisRNA, Long NoncodingBreast cancerEnrichment analysisGene expressionImmune infiltrationIn vitro and in vivo experimentsLong noncoding RNA SPACA6P-AS

Identifiers

PMID38922500
PMCPMC11208203

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.